Literature DB >> 17763374

1-cinnamyl-4-(2-methoxyphenyl)piperazines: synthesis, binding properties, and docking to dopamine (D(2)) and serotonin (5-HT(1A)) receptors.

Jelena Penjisević1, Vladimir Sukalović, Deana Andrić, Sladjana Kostić-Rajacić, Vukić Soskić, Goran Roglić.   

Abstract

Clinical properties of atypical antipsychotics are based on their interaction with D(2) dopamine receptor and serotonin 5-HT(1A) and 5-HT(2A) receptors. As a part of our research program on new antipsychotics, we synthesized various derivatives of 1-cinnamyl-4-(2-methoxyphenyl)piperazines, and evaluated their affinities for D(2), 5-HT(1A), 5-HT(2A), and adrenergic (alpha(1)) receptors using radioligand-binding assays. In addition, we performed docking analysis using models for the D(2) and 5-HT(1A) receptors. All compounds exhibited low to moderate affinity to 5-HT(1A) and 5-HT(2A) receptors, high affinity to the D(2 )receptor and large variability in affinities for the alpha(1) receptor. Docking analysis indicated that the binding to D(2) and 5-HT(1A) receptors is based on (i) interaction between protonated N1 of the piperazine ring and various aspartate residues, (ii) hydrogen bonds between various moieties of the ligand and the residues of threonine, serine, histidine or tryptophane, and (iii) edge-to-face interactions of the aromatic ring of the arylpiperazine moiety with phenylalanine or tyrosine residues. Docking data for the D(2) receptor can account for the binding properties obtained in binding assays, suggesting that the model is reliable and robust. However, docking data for the 5-HT(1A) receptor cannot account for actual binding properties, suggesting that further refinement of the model is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763374     DOI: 10.1002/ardp.200700062

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  4 in total

1.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

2.  1,1'-(Piperazine-1,4-di-yl)dipropan-2-ol.

Authors:  Murat Türkyılmaz; Yakup Baran; Namık Ozdemir
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-06-22

3.  Crystal structure of 4-(2-meth-oxy-phen-yl)piper-azin-1-ium 3,5-dintrosalicylate.

Authors:  Veerappan Subha; Thangaraj Seethalakshmi; Thangavelu Balakrishnan; M Judith Percino; Perumal Venkatesan
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2022-07-12

4.  Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study.

Authors:  Seungyeon Kim; Yun Mi Yu; Jeongyoon Kwon; Kyeong Hye Jeong; Jeong Sang Lee; Euni Lee
Journal:  Int J Environ Res Public Health       Date:  2020-10-04       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.